Biogen beats estimates on multiple sclerosis therapy sales Reuters

Biogen beats estimates on multiple sclerosis therapy sales Reuters

Source: 
Yahoo/Reuters
snippet: 

Drugmaker Biogen Inc beat analysts' estimates for quarterly profit and lifted its 2019 earnings forecast on Tuesday, driven by higher sales of its top-selling multiple sclerosis therapy Tecfidera.